现代肿瘤医学
現代腫瘤醫學
현대종류의학
Journal of Modern Oncology
2015年
22期
3271-3273
,共3页
韩起鹏%姜力%孙刚%田华%王德权%罗小冬%陈宇
韓起鵬%薑力%孫剛%田華%王德權%囉小鼕%陳宇
한기붕%강력%손강%전화%왕덕권%라소동%진우
肾癌%干扰素%免疫
腎癌%榦擾素%免疫
신암%간우소%면역
renal cell carcinoma%interferon%immunity
目的:评价肾癌患者术后应用干扰素免疫治疗对机体免疫水平的影响。方法:选取肾癌患者50例,术后应用干扰素(IFN)行免疫治疗,同时选取术后未行免疫治疗的肾癌患者45例作为对照组。于术前及术后1、2、3个月检测患者免疫指标(CD3+、CD4+、CD8+、CD4+/CD8+、CD19+、CD16+56+),比较两组间指标差异及手术前后免疫指标变化情况。结果:术前免疫治疗组与对照组间各项免疫指标差异无统计学意义(P >0.05)。术后1、2、3个月对照组各免疫指标与术前相比差异无统计学意义(P 均>0.05),治疗组术后第2、3个月较术前均有显著差异(P <0.05、P <0.01)。结论:肾癌术后应用干扰素免疫治疗能有效提高机体免疫水平,对患者远期预后需进一步随访。
目的:評價腎癌患者術後應用榦擾素免疫治療對機體免疫水平的影響。方法:選取腎癌患者50例,術後應用榦擾素(IFN)行免疫治療,同時選取術後未行免疫治療的腎癌患者45例作為對照組。于術前及術後1、2、3箇月檢測患者免疫指標(CD3+、CD4+、CD8+、CD4+/CD8+、CD19+、CD16+56+),比較兩組間指標差異及手術前後免疫指標變化情況。結果:術前免疫治療組與對照組間各項免疫指標差異無統計學意義(P >0.05)。術後1、2、3箇月對照組各免疫指標與術前相比差異無統計學意義(P 均>0.05),治療組術後第2、3箇月較術前均有顯著差異(P <0.05、P <0.01)。結論:腎癌術後應用榦擾素免疫治療能有效提高機體免疫水平,對患者遠期預後需進一步隨訪。
목적:평개신암환자술후응용간우소면역치료대궤체면역수평적영향。방법:선취신암환자50례,술후응용간우소(IFN)행면역치료,동시선취술후미행면역치료적신암환자45례작위대조조。우술전급술후1、2、3개월검측환자면역지표(CD3+、CD4+、CD8+、CD4+/CD8+、CD19+、CD16+56+),비교량조간지표차이급수술전후면역지표변화정황。결과:술전면역치료조여대조조간각항면역지표차이무통계학의의(P >0.05)。술후1、2、3개월대조조각면역지표여술전상비차이무통계학의의(P 균>0.05),치료조술후제2、3개월교술전균유현저차이(P <0.05、P <0.01)。결론:신암술후응용간우소면역치료능유효제고궤체면역수평,대환자원기예후수진일보수방。
Objective:To evaluate the change of immune function in postoperative patients with renal cell carcino-ma treated with interferon.Methods:Fifty patients with renal cell carcinoma treated with interferon after operation consisted of the treatment group.The control group included 45 patients without any treatment after operation.Immune parameters,including CD3 +,CD4 +,CD8 +,CD4 +/CD8 +,CD19 + and CD16 +56 + were determined before and at the 1th,2nd,3th month after therapy.Results:The levels of detected immune parameters had no statistic difference before operation(P >0.05)between the two groups.In control group,the levels of immune parameters had no statistic differ-ence at the 1th,2nd,3th month after operation(P >0.05).However,statistic difference was found in treatment group at the 2nd and 3th month after operation(P <0.05,P <0.01).Conclusion:Interferon can increase the immune level of patients with renal cell carcinoma after operation,and its influence on the long -term survival needs further study.